The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERN1, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells

Lavitrano, M., Grassilli, E., Helin, K. (2008)Btk inhibitors for use in treating chemotherapeutic drug-resistant epithelial tumours. . Brevetto No. EP20080717840.

Btk inhibitors for use in treating chemotherapeutic drug-resistant epithelial tumours

LAVITRANO, MARIALUISA;GRASSILLI, EMANUELA;
2008

Abstract

The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERN1, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells
Si
siRNA, drug resistance, epithelial tumors
Human necessities
Rilevanza europea
EP20080717840
23-dic-2009
EP2134374
20-nov-2013
EP2134374 B1
Altro titolare
Lavitrano, M; Grassilli, E; Helin, K
Lavitrano, M., Grassilli, E., Helin, K. (2008)Btk inhibitors for use in treating chemotherapeutic drug-resistant epithelial tumours. . Brevetto No. EP20080717840.
File in questo prodotto:
File Dimensione Formato  
EP_2134374_B1.pdf

Solo gestori archivio

Dimensione 425.55 kB
Formato Adobe PDF
425.55 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/61770
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
Social impact